MX9704579A - Composicion farmaceutica que comprende mirtazapina y uno o mas inhibidores selectivos de reabsorcion de serotonina. - Google Patents
Composicion farmaceutica que comprende mirtazapina y uno o mas inhibidores selectivos de reabsorcion de serotonina.Info
- Publication number
- MX9704579A MX9704579A MX9704579A MX9704579A MX9704579A MX 9704579 A MX9704579 A MX 9704579A MX 9704579 A MX9704579 A MX 9704579A MX 9704579 A MX9704579 A MX 9704579A MX 9704579 A MX9704579 A MX 9704579A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- myrtazpine
- serotonine
- ssri
- reabsorption inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion se refiere a una composicion farmacéutica que comprende mirtazapina, un inhibidor selectivo de reabsorcion de serotonina (SSRI) y auxiliares farmacéuticamente aceptables. En particular, el SSRI se selecciona de fluoxetina, fluvoxamina, citalopram, cericlamina, fexometina, sertralina, paroxetina, ifoxetina, cianodotiepin y litoxetina. La composicion, la cual puede ser utilizada para tratar pacientes con depresion, tiene menos efectos laterales que el tratamiento de los pacientes con mirtazapina o el SSRI solo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201703 | 1996-06-19 | ||
| EP96201703.4 | 1996-06-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9704579A true MX9704579A (es) | 1998-07-31 |
| MXPA97004579A MXPA97004579A (es) | 1998-11-09 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2208199A1 (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| AU7321598A (en) | Use of cholinesterase inhibitors to treat disorders of attention | |
| AU3419995A (en) | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence | |
| IS7764A (is) | Glútamín-þíasólidíð og -pýrrólidíð og notkun þeirra sem dípeptidýlpeptíðasa IV hindrar | |
| MXPA05006194A (es) | Metodo para utilizar una composicion de bebida. | |
| DE69828408D1 (de) | Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung | |
| WO2001024816A3 (en) | Compositions and methods relating to the inhibition of casomorphin and gluteomorphin | |
| NZ514628A (en) | Use of inhibitors for inducing cancer cell death and tumor regression | |
| NZ514450A (en) | Use of dipeptidyl peptidase IV inhibitors for promoting growth | |
| AU2001248701A1 (en) | Inhibitors of histone deacetylase | |
| ES2196190T3 (es) | Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico. | |
| BR9714385A (pt) | Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular | |
| NZ223400A (en) | Dental composition containing kappa-caseino-glycopeptides | |
| MY114347A (en) | Synergistic therapeutic compositions and methods. | |
| CA2304657A1 (en) | Treatment of conduct disorder | |
| BR0107749A (pt) | Métodos de uso de uma composição de bebida | |
| NZ503962A (en) | ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis | |
| AU2002363182A1 (en) | Smad7 inhibitors for the treatment of cns diseases | |
| DE69433092D1 (de) | Getränk mit einem gehalt an alpha-ketoglutarsäure | |
| UA94922C2 (ru) | Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора | |
| DE69725860D1 (de) | PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN | |
| BRPI0410467A (pt) | composições e métodos para tratamento de sìndrome respiratória aguda severa (sars) | |
| WO2001034172A3 (en) | Methods and compositions for treating reward deficiency syndrome | |
| IS2097B (is) | Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni | |
| WO2003004006A8 (en) | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: N.V. ORGANON.* |
|
| MM | Annulment or lapse due to non-payment of fees |